High-dose continuous infusion plus pulse interleukin-2 and famotidine in metastatic kidney cancer

Cancer Biotherapy and Radiopharmaceuticals

Volumn 20, Issue 1, 2005, Pages 36-40

  Quan Jr , Walter ^a   Ramirez, Maria ^b   Taylor, Chris ^b   Vinogradov, Mikhail ^b   Quan, Francine ^a   Khan, Nawazish ^b  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Famotidine; Interleukin 2; Kidney cancer; Lymphokine activated killer cell (LAK); Renal cancer

Indexed keywords

DOPAMINE; FAMOTIDINE; FUROSEMIDE; RECOMBINANT INTERFERON; RECOMBINANT INTERLEUKIN 2; THALIDOMIDE;

ARTICLE; BONE METASTASIS; CANCER SURVIVAL; CAUSE OF DEATH; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG FEVER; DRUG MEGADOSE; DRUG PULSE THERAPY; DYSPNEA; FATIGUE; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; INTENSIVE CARE; KIDNEY CANCER; LIVER TOXICITY; LUNG EDEMA; LUNG METASTASIS; LYMPH NODE METASTASIS; MALAISE; METABOLIC ACIDOSIS; NAUSEA; OXYGEN SUPPLY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RIGOR; SIDE EFFECT; TACHYCARDIA; THORAX RADIOGRAPHY; TREATMENT FAILURE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; FAMOTIDINE; FEMALE; HISTAMINE H2 ANTAGONISTS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; KIDNEY NEOPLASMS; KILLER CELLS, LYMPHOKINE-ACTIVATED; MALE; MIDDLE AGED; NEOPLASM METASTASIS; TIME FACTORS;

EID: 16444382314     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2005.20.36     Document Type: Article

References (22)

1. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 therapy in patients with renal cell carcinoma. Cancer J Sci Am 2000;6(Suppl 1)S11.
2. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 1994;271:907.
3. Hawkins MJ. Interleukin-2 antitumor and effector cell responses. Semin Oncol 1993;20(Suppl 9):52.
4. Papa MZ, Mule JJ, Rosenberg SA. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin in vivo: Successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three distinct histologic types. Cancer Res 1986;46:4973.
5. Dillman RO, Oldham RK, Tauer KW, et al. Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: A National Biotherapy Study Group trial. J Clin Oncol 1991;9:1233.
6. Weiss GR, Margolin KA, Aronson FR, et al. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. J Clin Oncol 1992;10:275.
7. Dillman RO, Church C, Oldham RK, et al. Inpatient continuous-infusion interleukin-2 in 788 patients with cancer. The National Biotherapy Study Group experience. Cancer 1993;71:2358.
8. Dillman RO, Wiemann MC, Bury MJ, et al. Hybrid high-dose bolus/continuous infusion interleukin-2 in patients with metastatic renal cell carcinoma: A phase II trial of the National Biotherapy Study Group. Cancer Biother Radiopham 1997;12:5.
9. Sondel PM, Kohler PC, Hank JA, et al. Clinical and immunological effects of recombinant Interleukin-2 given by repetitive weekly cycles to patients with cancer. Cancer Res 1988;48:2561.
10. Sosman JA, Kohler PC, Hank J, et al. Repetitive weekly cycles of recombinant human interleukin-2: Responses of renal carcinoma with acceptable toxicity. J Natl Cancer Inst 1988;80:60.
11. Sosman JA, Kohler PC, Hank JA, et al. Repetitive weekly cycles of interleukin-2. Clinical and immunologic effects of dose, schedule, and addition of indomethacin. J Natl Cancer Inst 1988;80:1451.
12. Voss SD, Weil-Hillman G, Hank JA, et al. The clinical immunobiology of interleukin-2: Potential modified uses for improved cancer treatment. Bull NY Acad Med 1989;65:93.
13. Hanks JA, Weil-Hillman G, Surfus JE, et al. Addition of interleukin-2 in vitro augments detection of lymphokine-activated killer activity generated in vivo. Cancer Immunol Immunother 1990;31:53.
14. Horton SA, Oldham RK, Yannelli JR. Generation of human lymphokine-activated killer cells following brief exposure to high-dose interleukin-2. Cancer Res 1990;50:1686.
15. Parshad R, Kapoor S, Gupta SD, et al. Does famotidine enhance tumor-infiltrating lymphocytes in breast cancer? Results of a randomized prospective pilot study. Acta Oncol 2002;41:362.
16. Tsunoda T, Tanimura H, Yamaue H, et al. In vitro augmentation of the cytotoxic activity of peripheral blood mononuclear cells and tumor-infiltrating lymphocytes by famotidine in cancer patients. Int J Immunopharmacol 1992;14:75.
17. Quan WDY Jr, Quan FM. Outpatient experience with moderate-dose bolus interleukin-2 in metastatic malignant melanoma and kidney cancer. J Immunother 2003;26:286.
18. Weinrich DM, Rosenberg SA: Response rates of patients with metastatic melanoma to high-dose intravenous interleukin-2 after prior exposure to alpha-interferon or low-dose interleukin-2. J Immunother 2002;25:185.
19. Quan WDY Jr, Quan FM. Bolus followed by continuous infusion interleukin-2 in patients with metastatic malignant melanoma and kidney cancer previously treated with interleukin-2. Cancer Biother Radiopharm 2003;18:535.
20. Domzig W, Stadler BM, Herberman RB. Interleukin-2 dependence of human natural killer (LAK) cell activity. J Immunol 1983;130:1970.
21. Yang JC, Rosenberg SA. An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell carcinoma. Cancer J Sci Am 1997;3(Suppl 1):S79.
22. Gambacorti-Passerini C, Hank JA, Albertini MR, et al. A pilot phase II trial of continuous-infusion interleukin-2 followed by lymphokine-activated killer cell therapy and bolus-infusion interleukin-2 in renal cancer. J Immunother 1993;13:43.